Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sattva S Neelapu

Showing results (1-10 of 259) with videos related to

Pageof 26
Sort By:
Hematological Oncology|June 13, 2019
Managing the toxicities of CAR T-cell therapySattva S Neelapu
Clinical Advances in Hematology & Oncology : H&O|April 12, 2017
An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphomaSattva S Neelapu
Blood|January 24, 2015
Mutations and microenvironment collude in FLSattva S Neelapu
Blood|March 21, 2020
A CAR against CAR for unintended consequencesSattva S Neelapu
Blood|April 27, 2019
CAR-T efficacy: is conditioning the key?Sattva S Neelapu
Current Hematologic Malignancy Reports|April 29, 2010
Vaccination strategies in follicular lymphomaShibichakravarthy Kannan, Sattva S Neelapu
Current Oncology Reports|March 29, 2019
Chimeric Antigen Receptor-Engineered T Cell Therapy in LymphomaPaolo Strati, Sattva S Neelapu
Nature Medicine|September 15, 2022
CAR T<sub>r</sub><sub>e</sub><sub>g</sub> cells: prime suspects in therapeutic resistanceNeeraj Saini, Sattva S Neelapu
Molecular Oncology|November 10, 2015
Cancer immunotherapy: Strategies for personalization and combinatorial approachesVishwanath Sathyanarayanan, Sattva S Neelapu
Best Practice & Research. Clinical Haematology|September 15, 2018
The promise of CAR T-cell therapy in aggressive B-cell lymphomaRanjit Nair, Sattva S Neelapu
Pageof 26

Showing results (1-10 of 259) with videos related to

Sort By:
Pageof 26
Hematological Oncology|June 13, 2019
Managing the toxicities of CAR T-cell therapySattva S Neelapu
Clinical Advances in Hematology & Oncology : H&O|April 12, 2017
An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphomaSattva S Neelapu
Blood|January 24, 2015
Mutations and microenvironment collude in FLSattva S Neelapu
Blood|March 21, 2020
A CAR against CAR for unintended consequencesSattva S Neelapu
Blood|April 27, 2019
CAR-T efficacy: is conditioning the key?Sattva S Neelapu
Current Hematologic Malignancy Reports|April 29, 2010
Vaccination strategies in follicular lymphomaShibichakravarthy Kannan, Sattva S Neelapu
Current Oncology Reports|March 29, 2019
Chimeric Antigen Receptor-Engineered T Cell Therapy in LymphomaPaolo Strati, Sattva S Neelapu
Nature Medicine|September 15, 2022
CAR T<sub>r</sub><sub>e</sub><sub>g</sub> cells: prime suspects in therapeutic resistanceNeeraj Saini, Sattva S Neelapu
Molecular Oncology|November 10, 2015
Cancer immunotherapy: Strategies for personalization and combinatorial approachesVishwanath Sathyanarayanan, Sattva S Neelapu
Best Practice & Research. Clinical Haematology|September 15, 2018
The promise of CAR T-cell therapy in aggressive B-cell lymphomaRanjit Nair, Sattva S Neelapu
Pageof 26